Date: 07 July 2014

Description: A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of serious skin reactions, namely Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), associated with Vectibix^®.This product should be discontinued if SJS/TEN is suspected. The package inserts for Vectibix^® will be updated by GlaxoSmithKline Pharmaceuticals (Malaysia) Sdn. Bhd. to reflect this new safety information. Please refer to the DHPC for further information.